A Warm Welcome from Prof. Francesco Giorgino | EASD 2025
&feature=youtu.be
Landmark Collaboration: CACA-LCC and ILCA Forge Strategic Partnership to Advance Global Hepatocellular Carcinoma Research and Treatment
Guangzhou, China, July 26, 2025 — In a significant move to advance global efforts in the fight against hepatocellular carcinoma (HCC), the Chinese Anti-Cancer Association Liver Cancer Committee (CACA-LCC) and…
Blood Science Update | Unlocking TRAIL’s Potential in Hematologic Malignancies: Mechanisms, Resistance, and Emerging Therapeutic Strategies
Hematologic malignancies such as leukemia, lymphoma, and multiple myeloma remain among the most challenging cancers to treat due to high relapse rates and treatment resistance. Tumor necrosis factor-related apoptosis-inducing ligand…
Blood Science Update | Advancing the Diagnosis and Management of Primary Vitreoretinal Lymphoma: New Insights and Future Perspectives
Primary vitreoretinal lymphoma (PVRL) is a rare but highly aggressive intraocular malignancy closely associated with primary central nervous system lymphoma (PCNSL). Characterized by vague symptoms and high rates of misdiagnosis,…
Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions
ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess expectations surrounding NUTM1 fusion-positive leukemias and investigate the biological complexity behind treatment failure.
IDSC 2025丨Professor Yoshiaki Gu: From National Action to One Health Strategy – Japan’s Experience and Future Pathways in AMR Control
ntimicrobial resistance (AMR) has become a major global public health challenge. To enhance capabilities in diagnosing and treating infectious diseases and promote rational use of antimicrobial agents in China, the 11th Academic Conference of the Infectious Diseases Society of China (IDSC) under the China Medicine Education Association was recently held in Beijing. At the conference, Professor Yoshiaki Gu from the Institute of Science Tokyo (Science Tokyo) shared Japan’s experience in AMR control. Infectious Disease Frontier invited Professor Gu to provide an in-depth analysis of the evolving threat of drug-resistant pathogens in Japan, the outcomes of its National Action Plan, and innovative public education initiatives. He further explored critical future directions for antimicrobial drug development and cross-sectoral collaboration under the "One Health" strategy.
Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress
From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.
Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci
Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.
EHA Expert Interview | Professor John Mascarenhas on INCA33989: A Breakthrough Monoclonal Antibody Therapy for Essential Thrombocythemia
Essential thrombocythemia (ET) is a common myeloproliferative neoplasm characterized by elevated platelet counts, thrombotic and hemorrhagic events, and significantly impaired quality of life. At the 2025 European Hematology Association (EHA)…